Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Improving analgesia prescription for trauma inpatients.

Stanger S, Dahill M, Hillary C, Whitham R, Tasker A.

BMJ Open Qual. 2018 Dec 16;7(4):e000397. doi: 10.1136/bmjoq-2018-000397. eCollection 2018.

2.

The use of low-intensity pulsed ultrasound in treating delayed union of fifth metatarsal fractures.

Teoh KH, Whitham R, Wong JF, Hariharan K.

Foot (Edinb). 2018 Jun;35:52-55. doi: 10.1016/j.foot.2018.01.004. Epub 2018 Jan 31.

PMID:
29793139
3.

R3 Cup Does Not Have a High Failure Rate in Conventional Bearings: A Minimum of 5-Year Follow-Up.

Teoh KH, Whitham RDJ, Golding DM, Wong JF, Lee PYF, Evans AR.

J Arthroplasty. 2018 Feb;33(2):460-463. doi: 10.1016/j.arth.2017.09.059. Epub 2017 Oct 7.

PMID:
29107497
4.

Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness.

Bourdette D, Whitham R.

Neurology. 2016 Oct 11;87(15):1532-1533. Epub 2016 Sep 2. No abstract available.

PMID:
27590289
5.

The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG.

Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.

6.
7.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866143
8.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866141
9.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866072
10.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866070
11.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Hartung DM, Bourdette DN, Ahmed SM, Whitham RH.

Neurology. 2015 May 26;84(21):2185-92. doi: 10.1212/WNL.0000000000001608. Epub 2015 Apr 24. Erratum in: Neurology. 2015 Nov 10;85(19):1728.

12.

Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis.

Wegmann KW, Archie Bouwer HG, Whitham RH, Hinrichs DJ.

J Neuroimmunol. 2014 Sep 15;274(1-2):46-52. doi: 10.1016/j.jneuroim.2014.06.011. Epub 2014 Jun 26.

PMID:
24997489
13.

Reducing survey burden: feasibility and validity of PROMIS measures in multiple sclerosis.

Senders A, Hanes D, Bourdette D, Whitham R, Shinto L.

Mult Scler. 2014 Jul;20(8):1102-11. doi: 10.1177/1352458513517279. Epub 2014 Jan 8.

14.

Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.

Cameron MH, Fitzpatrick M, Overs S, Murchison C, Manning J, Whitham R.

Mult Scler. 2014 May;20(6):733-8. doi: 10.1177/1352458513507356. Epub 2013 Oct 7.

PMID:
24099749
15.

Access to multiple sclerosis specialty care.

Turner AP, Chapko MK, Yanez D, Leipertz SL, Sloan AP, Whitham RH, Haselkorn JK.

PM R. 2013 Dec;5(12):1044-50. doi: 10.1016/j.pmrj.2013.07.009. Epub 2013 Aug 3.

PMID:
23920332
16.

Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal.

Solomon AJ, Hills W, Chen Z, Rosenbaum J, Bourdette D, Whitham R.

PLoS One. 2013 Jun 12;8(6):e65385. doi: 10.1371/journal.pone.0065385. Print 2013.

17.

Targeting T cells responsive to the priming epitope prevent the relapsing phase of experimental autoimmune encephalomyelitis.

Wegmann KW, Bouwer HG, Gregory CR, Whitham RH, Hinrichs DJ.

J Neuroimmunol. 2013 Jul 15;260(1-2):74-81. doi: 10.1016/j.jneuroim.2013.04.001. Epub 2013 Apr 20.

PMID:
23611642
18.

Arts-based learning: is it worthwhile?

Whitham R, Rose E, Cain R.

Med Educ. 2012 Apr;46(4):437. doi: 10.1111/j.1365-2923.2011.04200.x. No abstract available.

PMID:
22429181
19.

American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study.

Kim E, Cameron M, Lovera J, Schaben L, Bourdette D, Whitham R.

Mult Scler. 2011 Dec;17(12):1523-6. doi: 10.1177/1352458511412062. Epub 2011 Jul 29.

PMID:
21803872
20.

Simulation centers and the surgical trainee: a response from the UK.

Whitham R, Ved R, Cooksey F.

J Surg Educ. 2011 Mar-Apr;68(2):98. doi: 10.1016/j.jsurg.2010.12.007. No abstract available.

PMID:
21338962
21.
22.

Novel method for measurement of fatigue in multiple sclerosis: Real-Time Digital Fatigue Score.

Kim E, Lovera J, Schaben L, Melara J, Bourdette D, Whitham R.

J Rehabil Res Dev. 2010;47(5):477-84.

23.

Multiple sclerosis and vitamin D: a review and recommendations.

Solomon AJ, Whitham RH.

Curr Neurol Neurosci Rep. 2010 Sep;10(5):389-96. doi: 10.1007/s11910-010-0131-5. Review.

PMID:
20556546
24.

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial.

Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, Stuve O, Karman J, Bogardus K, Heimburger G, Cua L, Remingon G, Fowler J, Monahan T, Kilcup S, Courtney Y, McAleenan J, Butler K, Wild K, Whitham R, Bourdette D.

Mult Scler. 2010 Jun;16(6):715-23. doi: 10.1177/1352458510367662. Epub 2010 May 18.

PMID:
20483885
25.

Nephrogenic systemic fibrosis presenting as myopathy: a case report with histopathologic correlation.

Edgar E, Woltjer R, Whitham R, Gultekin SH, Watnick S, Cupler EJ.

Neuromuscul Disord. 2010 Jun;20(6):411-3. doi: 10.1016/j.nmd.2010.04.001. Epub 2010 May 11.

PMID:
20462761
26.

Immunotherapy and multiple sclerosis: The devil is in the details.

Bourdette D, Whitham R.

Neurology. 2010 May 4;74(18):1410-1. doi: 10.1212/WNL.0b013e3181dc1b36. No abstract available.

PMID:
20439842
27.

Synthetic Peptide dendrimers block the development and expression of experimental allergic encephalomyelitis.

Wegmann KW, Wagner CR, Whitham RH, Hinrichs DJ.

J Immunol. 2008 Sep 1;181(5):3301-9.

28.

Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.

Vandenbark AA, Culbertson NE, Bartholomew RM, Huan J, Agotsch M, LaTocha D, Yadav V, Mass M, Whitham R, Lovera J, Milano J, Theofan G, Chou YK, Offner H, Bourdette DN.

Immunology. 2008 Jan;123(1):66-78. Epub 2007 Oct 16.

29.

Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial.

Lovera J, Bagert B, Smoot K, Morris CD, Frank R, Bogardus K, Wild K, Oken B, Whitham R, Bourdette D.

Mult Scler. 2007 Apr;13(3):376-85. Epub 2007 Jan 29.

PMID:
17439907
30.

Correlations of Perceived Deficits Questionnaire of Multiple Sclerosis Quality of Life Inventory with Beck Depression Inventory and neuropsychological tests.

Lovera J, Bagert B, Smoot KH, Wild K, Frank R, Bogardus K, Oken BS, Whitham RH, Bourdette DN.

J Rehabil Res Dev. 2006 Jan-Feb;43(1):73-82.

31.

Exploring educational needs of multiple sclerosis care providers: Results of a care-provider survey.

Turner AP, Martin C, Williams RM, Goudreau K, Bowen JD, Hatzakis M Jr, Whitham RH, Bourdette DN, Walker L, Haselkorn JK.

J Rehabil Res Dev. 2006 Jan-Feb;43(1):25-34.

32.

A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis.

Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, Simon J, Whitham R, Lovera J, Yadav V, Mass M, Spencer L, Culbertson N, Bartholomew RM, Theofan G, Milano J, Offner H, Vandenbark AA.

Mult Scler. 2005 Oct;11(5):552-61.

PMID:
16193893
33.

Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants.

Buenafe AC, Tsaknaridis L, Spencer L, Hicks KS, McMahan RH, Watson L, Culbertson NE, Latocha D, Wegmann K, Finn T, Bartholomew R, Burrows GG, Whitham R, Bourdette DN, Jones RE, Offner H, Chou YK, Vandenbark AA.

J Neurosci Res. 2004 Apr 1;76(1):129-40.

PMID:
15048937
34.

Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity.

Tsaknaridis L, Spencer L, Culbertson N, Hicks K, LaTocha D, Chou YK, Whitham RH, Bakke A, Jones RE, Offner H, Bourdette DN, Vandenbark AA.

J Neurosci Res. 2003 Oct 15;74(2):296-308.

PMID:
14515359
35.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weistock-Guttman B, Whitham RH; Multiple Sclerosis Collaborative Research Group.

Neurology. 2001 Dec;57(12 Suppl 5):S25-30. No abstract available.

PMID:
11902591
36.

Diminished frequency of interleukin-10-secreting, T-cell receptor peptide-reactive T cells in multiple sclerosis patients might allow expansion of activated memory T cells bearing the cognate BV gene.

Vandenbark AA, Finn T, Barnes D, Culbertson N, Chou YK, Hicks K, Bakke A, Mass M, Whitham R, Offner H, Bourdette D.

J Neurosci Res. 2001 Oct 15;66(2):171-6.

PMID:
11592112
37.

TCR peptide therapy in human autoimmune diseases.

Vandenbark AA, Morgan E, Bartholomew R, Bourdette D, Whitham R, Carlo D, Gold D, Hashim G, Offner H.

Neurochem Res. 2001 Jun;26(6):713-30. Review.

PMID:
11519731
38.

Differential susceptibility of human T(h)1 versus T(h) 2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells.

Vandenbark AA, Barnes D, Finn T, Bourdette DN, Whitham R, Robey I, Kaleeba J, Bebo BF Jr, Miller SD, Offner H, Chou YK.

Int Immunol. 2000 Jan;12(1):57-66.

PMID:
10607750
39.

Expression of a functional antibody fragment in the gut of Rhodnius prolixus via transgenic bacterial symbiont Rhodococcus rhodnii.

Durvasula RV, Gumbs A, Panackal A, Kruglov O, Taneja J, Kang AS, Cordon-Rosales C, Richards FF, Whitham RG, Beard CB.

Med Vet Entomol. 1999 May;13(2):115-9.

PMID:
10484156
40.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al.

J Neuroimmunol. 1999 Jan 1;93(1-2):8-14.

PMID:
10378864
41.

IL-7 enhances Ag-specific human T cell response by increasing expression of IL-2R alpha and gamma chains.

Chou YK, Bourdette DN, Barnes D, Finn TP, Murray S, Unsicker L, Robey I, Whitham RH, Buenafe AC, Allegretta M, Offner H, Vandenbark AA.

J Neuroimmunol. 1999 Apr 1;96(1):101-11.

PMID:
10227429
42.

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM, Fischer JS, Jacobs LD, Cookfair DL, Rudick RA, Richert JR, Salazar AM, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Whitham RH, et al.

Mult Scler. 1998 Dec;4(6):480-6.

PMID:
9987756
44.

Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes.

Bourdette DN, Chou YK, Whitham RH, Buckner J, Kwon HJ, Nepom GT, Buenafe A, Cooper SA, Allegretta M, Hashim GA, Offner H, Vandenbark AA.

J Immunol. 1998 Jul 15;161(2):1034-44.

45.
46.

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH, et al.

Ann Neurol. 1998 Jan;43(1):79-87.

PMID:
9450771
47.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Whitham RH, et al.

Neurology. 1997 Aug;49(2):358-63.

PMID:
9270562
48.

Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.

Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, O'Connor P, Cohen JA, Schapiro RT, Whitham R, Mass MK, Lindsey JW, Shellenberger K.

Arch Neurol. 1997 Jun;54(6):731-6.

PMID:
9193208
49.

Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial.

Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeld D, Kavanagh D, Cooper S, Hashim GA, Offner H.

Nat Med. 1996 Oct;2(10):1109-15. Erratum in: Nat Med 1997 Feb;3(2):240.

PMID:
8837609
50.

MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR V beta CDR2 peptides: comparison with myelin basic protein-specific T cells.

Chou YK, Weinberg AD, Buenafe A, Bourdette DN, Whitham R, Kaleeba JA, Robey IF, Kavanagh DG, Offner H, Vandenbark AA.

J Neurosci Res. 1996 Sep 15;45(6):838-51.

PMID:
8892096

Supplemental Content

Loading ...
Support Center